Compare SER & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | BNGO |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 24.3M |
| IPO Year | 2018 | 2018 |
| Metric | SER | BNGO |
|---|---|---|
| Price | $1.70 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.00 | $6.33 |
| AVG Volume (30 Days) | ★ 3.6M | 314.7K |
| Earning Date | 03-23-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,000.00 | ★ $28,720,000.00 |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $1.06 |
| 52 Week High | $7.92 | $6.32 |
| Indicator | SER | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 25.32 |
| Support Level | $2.11 | $1.06 |
| Resistance Level | $3.14 | $1.23 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 2.03 | 3.64 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.